STAT3 and familial pancreatic carcinoma: Our results are in agreement with other studies on the binding mode of STAT inhibitors, e.g., Arpin et al. (52) who reported a novel STAT3 small molecule inhibitor PG-S3-001 as a pancreatic cancer therapeutic.